Tesamorelin

Results: 9



#Item
1EMAIL TUS PREGUNTAS AL  www.projectinform.org/preguntas ENERO DEEl tesamorelin y el exceso

EMAIL TUS PREGUNTAS AL www.projectinform.org/preguntas ENERO DEEl tesamorelin y el exceso

Add to Reading List

Source URL: www.projectinform.org

Language: Spanish - Date: 2011-07-06 19:40:14
    2Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

    Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

    Add to Reading List

    Source URL: hc-sc.gc.ca

    Language: French - Date: 2014-05-12 14:23:37
      3Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-eng.docx

      Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-eng.docx

      Add to Reading List

      Source URL: hc-sc.gc.ca

      Language: English - Date: 2014-05-12 14:23:37
      4PRIOR AUTHORIZATION POLICY Egrifta™ (tesamorelin injection – EMD Serono) To initiate a Coverage Review, Call[removed]OVERVIEW Egrifta is an analog of human growth hormone-releasing factor (GRF), indicated for

      PRIOR AUTHORIZATION POLICY Egrifta™ (tesamorelin injection – EMD Serono) To initiate a Coverage Review, Call[removed]OVERVIEW Egrifta is an analog of human growth hormone-releasing factor (GRF), indicated for

      Add to Reading List

      Source URL: statehealthplan.state.nc.us

      Language: English - Date: 2013-10-03 14:58:53
      51) Please comment on the findings of glucose intolerance and development of diabetes associated with Egrifta (tesamorelin) therapy and its impact on long-term cardiovascular risk

      1) Please comment on the findings of glucose intolerance and development of diabetes associated with Egrifta (tesamorelin) therapy and its impact on long-term cardiovascular risk

      Add to Reading List

      Source URL: www.fda.gov

      Language: English
      6Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

      Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

      Add to Reading List

      Source URL: www.hc-sc.gc.ca

      Language: French - Date: 2014-05-12 14:23:37
        7Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-eng.docx

        Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-eng.docx

        Add to Reading List

        Source URL: www.hc-sc.gc.ca

        Language: English - Date: 2014-05-12 14:23:37
        8THERATECHNOLOGIES OBTAINS U.S. PATENT TERM EXTENSION FOR TESAMORELIN Montreal, Canada – June 9, 2014 —Theratechnologies Inc. (TSX: TH) today announced that the United States Patent and Trademark Office (USPTO) has is

        THERATECHNOLOGIES OBTAINS U.S. PATENT TERM EXTENSION FOR TESAMORELIN Montreal, Canada – June 9, 2014 —Theratechnologies Inc. (TSX: TH) today announced that the United States Patent and Trademark Office (USPTO) has is

        Add to Reading List

        Source URL: www.theratech.com

        Language: English - Date: 2014-06-10 09:56:59
        9Additional Update on Availability of EGRIFTA® (tesamorelin for injection) in the United States Montreal, Canada – May 23, 2014 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that following fu

        Additional Update on Availability of EGRIFTA® (tesamorelin for injection) in the United States Montreal, Canada – May 23, 2014 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that following fu

        Add to Reading List

        Source URL: www.theratech.com

        Language: English - Date: 2014-05-23 09:05:51